Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations

Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations

Abstract Immune checkpoint inhibitors (ICBs) have revolutionized cancer treatment producing remarkable and durable responses for a range of malignancies. However, the additional modulation of immune response by ICBs may rarely cause immune-related infectious complications, including re-activation of...

Full description

Bibliographic Details
Main Authors: Amalia Anastasopoulou, Dimitrios C. Ziogas, Michael Samarkos, John M. Kirkwood, Helen Gogas
Format: Article
Language:English
Published: BMJ Publishing Group 2019-09-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Immunotherapy
Cancer
Immune checkpoint inhibitors
Tuberculosis
Online Access:http://link.springer.com/article/10.1186/s40425-019-0717-7

Internet

http://link.springer.com/article/10.1186/s40425-019-0717-7

Similar Items